How are energy investors positioned?
LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company with a market capitalization of $58 million, has announced positive interim results from its Phase 1/2 NEXICART-2 clinical trial of NXC-201 in patients with relapsed/refractory AL Amyloidosis. The study showed a complete response rate of 71% with no relapses and a favorable safety profile. According to InvestingPro data, the company maintains a strong balance sheet with more cash than debt, though it’s currently experiencing rapid cash burn as it advances its clinical programs.
The trial, conducted across multiple U.S. centers, involved patients who had previously undergone an average of four lines of therapy for AL Amyloidosis. Following treatment with NXC-201, all participants normalized pathological disease markers, and complete responses were observed in 5 out of 7 patients. The remaining two patients showed minimum residual disease negativity, suggesting potential complete responses in the future.
Safety assessments revealed no serious adverse events related to NXC-201, with only low-grade cytokine release syndrome observed, lasting less than 24 hours. This safety profile, combined with the high response rate, marks a significant development in the treatment of AL Amyloidosis, a condition characterized by the buildup of abnormal proteins in organs, leading to organ failure and high mortality rates. With analysts setting a unanimous price target of $7.00, significantly above the current trading price of $2.41, InvestingPro subscribers can access detailed financial analysis and 8 additional key insights about IMMX’s growth potential.
The current treatments for relapsed/refractory AL Amyloidosis typically yield a complete response rate below 10%, highlighting the unmet need for more effective therapies. Immix Biopharma’s NXC-201, a sterically-optimized chimeric antigen receptor T (CAR-T) cell therapy, has also received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA.
Further detailed results, including endpoint analysis, are expected to be presented by lead investigator Heather Landau, MD, of Memorial Sloan Kettering Cancer Center, at the upcoming American Society of Clinical Oncology Annual Meeting (ASCO 2025) on June 3, 2025. A Key Opinion Leader event to discuss the significance of the findings is scheduled for the same day.
This announcement is based on a press release statement, and the information provided is subject to further verification by independent sources. The full results of the NEXICART-2 trial will be critical for evaluating the potential of NXC-201 to transform the treatment landscape for AL Amyloidosis. IMMX stock has shown strong momentum, delivering a 17% return over the past six months. Discover more comprehensive financial metrics and expert analysis with InvestingPro, including real-time updates on the company’s financial health score of 2.14, currently rated as ’FAIR’.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.